Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Transportation, E-Commerce & Mechanical Systems
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Citius Pharmaceuticals Inc. currently has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct examiners, meaning each pending matter is being reviewed by a different individual. This distribution requires the company to manage separate examiner relationships simultaneously within its active portfolio. The strategy for each case must be customized to the specific feedback provided by these 2 distinct examiners in the biotechnology field.
The 2 pending office actions are also located in 2 distinct art units, suggesting that the company's current pharmaceutical developments are being evaluated under different specialized criteria. HEITMEIER, KENDALL NICOLE is the busiest examiner with 1 pending office action. Because the busiest examiner pending count is 1, no single examiner holds a majority of the active workload. Practitioners must therefore address the specific requirements of the 2 distinct art units to advance these matters toward allowance. This spread across the USPTO ensures that the company's prosecution risks are not concentrated in a single group.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HEITMEIER, KENDALL NICOLE | 1 | 65.9% | +41.0% |
| LEE, ANDREW ELDRIDGE | 1 | 16.8% | +31.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19412192 | HALOBETASOL PROPIONATE-LIDOCAINE FORMULATIONS | HEITMEIER, KENDALL NICOLE | — |
| 18648288 | METHODS AND SYSTEMS FOR ASSESSING HEMORRHOIDS AND TREATMENT EFFECTIVENESS THEREOF | LEE, ANDREW ELDRIDGE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19412192 | HALOBETASOL PROPIONATE-LIDOCAINE FORMULATIONS | HEITMEIER, KENDALL NICOLE | — |
| 18648288 | METHODS AND SYSTEMS FOR ASSESSING HEMORRHOIDS AND TREATMENT EFFECTIVENESS THEREOF | LEE, ANDREW ELDRIDGE | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| 3684 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19412192 | HALOBETASOL PROPIONATE-LIDOCAINE FORMULATIONS | HEITMEIER, KENDALL NICOLE | 1621 | §101§103§112 | Non-Final OA | — | Pending | Dec 08, 2025 |
| 18648288 | METHODS AND SYSTEMS FOR ASSESSING HEMORRHOIDS AND TREATMENT EFFECTIVENESS THEREOF | LEE, ANDREW ELDRIDGE | 3684 | §101§102§103 | Final Rejection | — | Pending | Apr 26, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial